The $3.4 Billion Lesson Pharma Faces in Shelved Drugs
Thousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Passive strategies for retirement prioritize low costs and broad market exposure, delivering reliable long-term growth without constant tweaking.
23,939 articlesThousands of shelved drug candidates could unlock therapies for rare diseases, but funding and partnerships lag. The ...
Five major loan-channel partnerships in five days are redefining how borrowers learn about and secure loans. The rapi...
Energy markets move fast, but a 10-year horizon changes the game. This guide helps you identify what best energy stoc...
A late-breaking disclosure shows substantial purchases in Boeing and Nvidia by Donald Trump, as markets brace for a h...
KeyBanc boosts Okta's target to $103 from $95, citing a brighter security spending outlook and the central role of id...
Berkshire Hathaway reports a record cash and Treasury position, signaling Buffett’s readiness to act when markets dis...
Broadcom faces a fast-changing AI compute cycle that could lift shares toward $630, backed by custom silicon demand a...
Five weeks after Vanguard split three ETFs, VGT led the gauges, turning a post-split move into a meaningful performan...
Institutional holders control roughly 87% of Starbucks' float, and analysts expect further upside as comps improve an...
With summer on the horizon, energy markets react to travel demand and geopolitics. This guide highlights three energy...
AI is slashing underwriting time and accelerating document checks, but the real story is how regulatory guardrails ar...
Strategy’s flagship STRC yield product slid to yearly lows as Bitcoin volatility intensified, weighing on the company...